Approximately one in five subjects (19.3%) reported no side effects
In STEP-2 (NCT03552757), semaglutide (1.02.4 mg/week subcutaneously) reduced albuminuria by 25% versus placebo in normoalbuminuric patients with overweight/obesity but not T2DM and by 4157% in 166 participants with A2/A3 albuminuria [70]
Munson explains that the trend is going away from these types of drinks, as many athletes like to have more control over their refueling source, choosing a separate powder for electrolytes and using other mixes, gels, or chews as an energy source
were less likely to develop addictions to alcohol, nicotine, cocaine, opioids, and other substances than those treated with a different class of drugs
We have no clue how economic factors like tariffs could affect supply chains and price hikes, even for U.S.-formulated drugs (though Eli Lilly has been bracing for new tariffs on pharmaceuticals)
Their reasoning includes the potentially significant systemic side effects of stopping semaglutide and the lack of evidence for a causative link between GLP-1 RAs and NAION